Stock DAWN DAY ONE BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
13.27 USD -2.43% Intraday chart for Day One Biopharmaceuticals, Inc. -3.63% -9.11%
May. 30 Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million MT
May. 20 BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million
MT
Day One Announces Sale of Priority Review Voucher for $108 Million
GL
BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda
MT
HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating
MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
GL
North American Morning Briefing : Stock Futures -2-
DJ
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing
MT
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing
MT
North American Morning Briefing : Investors Brace -2-
DJ
Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating
MT
Transcript : Day One Biopharmaceuticals, Inc. - Special Call
Day One Biopharmaceuticals : Corporate Presentation - April 2024
PU
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
GL
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
AQ
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma
CI
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment
MT
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
DJ
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating
MT
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DAWN Stock
  4. News Day One Biopharmaceuticals, Inc.